ANUEVO Raises $22 Million in Series C Funding

ANUEVO, a Los Angeles-based medical technology company focused on non-invasive neuromodulation for spinal cord injury patients, announced the successful closing of a $22 million Series C funding round. The financing was led by Catcher Technology Co. Ltd., with participation from new investors.

Funding to Support Growth and Expansion

This new capital will be instrumental in supporting ANUEVO’s next phase of growth. Yi-Kai Lo, chief executive and co-founder of ANUEVO, stated, “This financing strengthens the operational and regulatory foundation required to responsibly scale ExaStim.” The company plans to focus on building manufacturing readiness, advancing regulatory initiatives, and expanding access in existing markets.

Key Areas of Investment

Proceeds from the Series C funding will be allocated to several key areas. These include executing commercial launch in approved markets, scaling manufacturing capabilities, and advancing regulatory activities within the United States.

About the ExaStim Stimulation System

The ExaStim Stimulation System is a non-invasive device designed to support functional neurorehabilitation for individuals with paralysis resulting from spinal cord injury. It delivers personalized spinal cord stimulation through a portable neurostimulation device.

How ExaStim Works

ExaStim utilizes a 16-channel, multi-electrode array to send pulses of electricity, stimulating nerves along the spinal cord and dorsal roots. The system is controlled using proprietary software on a mobile digital device. Currently, ExaStim is CE marked for use in the European Union and is limited to investigational use in the United States under Federal law.